RecruitingPhase 1NCT07698899

A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

A Phase I Dose Escalation Trial of Compartmental Radioimmunotherapy (cRIT) Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory B7H3 Expressing Primary or Metastatic CNS Tumors

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

18 participants

Start Date

Jul 2, 2026

Study Type

INTERVENTIONAL

Conditions

CNS Metastases Recurrent Medulloblastoma Refractory Medulloblastoma Central Nervous System Metastasis

Summary

The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.

Eligibility

Min Age: 3 YearsMax Age: 22 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called 25 mCi 177Lu- DTPA-omburtamab for people with cns metastases, central nervous system metastasis, and other related conditions. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 3 Years to 22 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.